GlassScriptPhysician profile
Lawrence D Atherton
NPI 1124033642
$5,790.51
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $612 · 2021: $867 · 2022: $1,442 · 2023: $1,493 · 2024: $20.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,582.80 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,016.45 | 2019-2024 | |
| Amgen INC. | $549.85 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.86 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $339.03 | 2021-2023 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $278.18 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $250.52 | 2022-2023 | Watchman Access System |
| Pfizer INC. | $220.86 | 2019-2023 | |
| Amarin Pharma, INC. | $192.64 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $146.12 | 2019-2023 | Farxiga |
| Edwards Lifesciences Corporation | $110.05 | 2019 | |
| Merck Sharp & Dohme LLC | $97.21 | 2022-2023 | Verquvo |
| Lundbeck LLC | $74.17 | 2019-2020 | |
| Abbott Laboratories | $71.13 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $67.92 | 2023 | Inpefa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $59.37 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $47.52 | 2019-2021 | |
| Daiichi Sankyo INC. | $40.12 | 2019-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $34.60 | 2021-2022 | |
| Vifor Pharma, INC. | $34.51 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $33.57 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $26.39 | 2019 | |
| Scpharmaceuticals INC. | $23.98 | 2023 | |
| Esperion Therapeutics, INC. | $18.64 | 2020 | |
| Astellas Pharma US INC | $15.63 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.26 | 2019 | |
| Medtronic Vascular, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Atherton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.